This morning, Basilea announced a further award of $30 million in non-dilutive funding as part of its agreement with BARDA to support the development of Basilea’s novel antifungal fosmanogepix. The payment has been received, as Basilea has met a pre-specified enrollment threshold in the ongoing Phase 3 programme. As a reminder, this funding is received under BARDA and Basilea’s 2024 ‘Other Transaction Agreement’, which awarded up to $268 million over 12 years. Overall, fundin

Basilea has announced that it has received a further significant funding tranche of $13.3m to fund the development of the Phase 3-ready combination antibiotic ceftibuten-ledaborbactam. This brings the total BARDA funding received to date for this programme to $25m, with the existing BARDA contract potentially providing an additional $133m in non-dilutive funding. Securing non-dilutive funding has been a rewarding characteristic of Basilea's anti-infective research & developme

We published a research note today, updating our outlook and forecasts for Basilea. Following a period of significant strategic and financial milestones, management is executing its "Agenda 2030," a roadmap to transition the company beyond its lead asset, Cresemba, and toward becoming a leading global powerhouse in anti-infectives. Bridging the "Cresemba Gap" While Cresemba continues to deliver strong sales—marketed in 76 countries and showing early-cycle growth in Japan and

Basilea announced this morning that it has been awarded additional non-dilutive funding of $6m from CARB-X for BAL2420 to fund the ongoing first-in-man Phase 1 study. BAL2420 has previously been supported by CARB-X funding, including $7.5m in 2024, as the programme moved towards the clinic. Overall we believe that the support from CARB-X represents a strong endorsement of this particular approach given CARB-X's focus on accelerating programmes targeting the WHO and CDC's Prio

Basilea announced this morning that its novel antibiotic to treat problematic Gram-negative infections has moved into first-in-human clinical studies. BAL2420 is targeting the lipopolysaccharide (LPS) transport bridge which helps maintain the integrity of the outer membrane in Gram-negative bacteria. Targeting LPS production and its transport machinery has already proven to be a productive approach in the development of antibiotics targeting the outer membrane of Gram-negativ

We like Genuit’s focus on climate change solutions and management’s unwavering commitment to invest capital in growth businesses